Penumbra, Inc. Names Shruthi Narayan as Company President
Penumbra (NYSE: PEN), a leading thrombectomy company, has appointed Shruthi Narayan as its new President, effective September 1, 2025. Narayan, who brings 20 years of medical device industry experience, will report to Adam Elsesser, who continues as chairman and CEO.
Previously serving as president of Penumbra's interventional business, Narayan joined the company in 2013 and has led significant growth in both neuro and vascular franchises. Her experience includes roles at Medtronic and extensive work in engineering, regulatory affairs, and cardiovascular sales.
Penumbra (NYSE: PEN), azienda leader nelle trombectomie, ha nominato Shruthi Narayan come nuova presidente, con decorrenza 1° settembre 2025. Narayan, che vanta 20 anni di esperienza nel settore dei dispositivi medici, risponderà ad Adam Elsesser, che rimane presidente del consiglio e CEO.
In precedenza presidente dell’area interventistica di Penumbra, Narayan è entrata in azienda nel 2013 e ha guidato una crescita significativa sia nelle divisioni neurologiche sia vascolari. Ha maturato esperienze in Medtronic e competenze approfondite in ingegneria, affari regolatori e vendite cardiovascolari.
Penumbra (NYSE: PEN), una empresa líder en trombectomía, ha nombrado a Shruthi Narayan como su nueva presidenta, con efecto a partir del 1 de septiembre de 2025. Narayan, que aporta 20 años de experiencia en la industria de dispositivos médicos, dependerá de Adam Elsesser, quien continuará como presidente y consejero delegado.
Anteriormente presidenta del negocio intervencionista de Penumbra, Narayan se incorporó a la compañía en 2013 y ha impulsado un crecimiento importante en las franquicias neuro y vascular. Su trayectoria incluye puestos en Medtronic y amplia experiencia en ingeniería, asuntos regulatorios y ventas cardiovasculares.
Penumbra (NYSE: PEN)는 선도적인 혈전제거(쓰롬벡토미) 기업으로, Shruthi Narayan을 2025년 9월 1일부로 신임 사장으로 임명했습니다. Narayan은 의료기기 업계에서 20년의 경험을 보유하고 있으며, 계속해서 회장 겸 CEO를 맡는 Adam Elsesser에게 보고할 예정입니다.
Penumbra의 인터벤셔널 사업부 사장을 역임한 Narayan은 2013년 회사에 합류해 신경 및 혈관 부문에서 큰 성장을 이끌었습니다. 그녀는 Medtronic에서의 근무 경험과 엔지니어링, 규제 업무, 심혈관 영업 분야의 폭넓은 경력을 갖추고 있습니다.
Penumbra (NYSE: PEN), entreprise leader en thrombectomie, a nommé Shruthi Narayan nouvelle présidente, à compter du 1er septembre 2025. Narayan, qui apporte 20 ans d’expérience dans l’industrie du dispositif médical, relèvera d’Adam Elsesser, qui reste président du conseil et PDG.
Précédemment présidente de l’activité interventionnelle de Penumbra, Narayan a rejoint la société en 2013 et a piloté une croissance significative des franchises neuro et vasculaires. Elle a travaillé chez Medtronic et possède une solide expérience en ingénierie, affaires réglementaires et ventes cardiovasculaires.
Penumbra (NYSE: PEN), ein führendes Thrombektomie-Unternehmen, hat Shruthi Narayan mit Wirkung zum 1. September 2025 zur neuen Präsidentin ernannt. Narayan, die über 20 Jahre Erfahrung in der Medizinproduktebranche verfügt, wird an Adam Elsesser berichten, der weiterhin Vorsitzender und CEO bleibt.
Zuvor war sie Präsidentin des interventionellen Geschäftsbereichs von Penumbra. Narayan kam 2013 zu dem Unternehmen und hat wesentliches Wachstum sowohl in den Neuro- als auch in den Gefäßbereichen vorangetrieben. Zu ihrer Laufbahn gehören Funktionen bei Medtronic sowie umfangreiche Erfahrungen in Ingenieurwesen, Regulatory Affairs und kardiovaskulärem Vertrieb.
- None.
- None.
"Shruthi is a dynamic, seasoned leader whose passion for innovation and proven ability to inspire global teams make her the obvious choice for this critical role," said Mr. Elsesser. "Her vision and focus on excellence will undoubtedly help sustain Penumbra's exceptional growth and market leadership, expanding access to our life-saving technology to patients around the world."
A 20-year veteran in the medical device industry, Ms. Narayan was most recently president of Penumbra's interventional business where she led the day-to-day operations and oversaw the growth initiatives of both the company's neuro and vascular franchises. She joined Penumbra in 2013 as a product manager starting off on the stroke franchise, then transitioning to help build the peripheral vascular division, commercializing Penumbra's vascular portfolio of embolization and thrombectomy products globally. Ms. Narayan began her medical device career at Medtronic in 2006, working in engineering, regulatory affairs and then in the cardiovascular sales organization.
"Penumbra has been at the forefront of blood clot care for more than 20 years, advancing the most innovative technologies to address conditions from head-to-toe like stroke and pulmonary embolism," said Ms. Narayan. "I am honored to carry on and expand our legacy of innovation and look forward to continuing this paradigm shift in patient care."
Ms. Narayan received a B.S. in Electrical Engineering from Anna University,
About Penumbra
Penumbra, Inc., the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, we support healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life. For more information, visit www.penumbrainc.com and connect on Instagram, LinkedIn and X.
Forward-Looking Statements
Except for historical information, certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements. Factors that could cause actual results to differ from those projected include, but are not limited to: failure to sustain or grow profitability or generate positive cash flows; failure to effectively introduce and market new products; delays in product introductions; significant competition; inability to further penetrate our current customer base, expand our user base and increase the frequency of use of our products by our customers; inability to achieve or maintain satisfactory pricing and margins; manufacturing difficulties; permanent write-downs or write-offs of our inventory or other assets; product defects or failures; unfavorable outcomes in clinical trials; inability to maintain our culture as we grow; fluctuations in foreign currency exchange rates; potential adverse regulatory actions; and the potential impact of any acquisitions, mergers, dispositions, joint ventures or investments we may make. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission ("SEC"), including our Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on February 18, 2025. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change.
Investor Relations
Penumbra, Inc.
investors@penumbrainc.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/penumbra-inc-names-shruthi-narayan-as-company-president-302539462.html
SOURCE Penumbra, Inc.
FAQ
Who is the new President of Penumbra (NYSE: PEN)?
What is Shruthi Narayan's background and experience at Penumbra?
What changes are happening to Penumbra's current leadership structure?
What is Shruthi Narayan's educational background?
What is Penumbra's main business focus?
